Biocept (BIOC) : During the past 4 weeks, traders have been relatively bearish on Biocept (BIOC), hence the stock is down -9.8% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -10.72% relative to the S&P 500. The 4-week change in the price of the stock is -8.87% and the stock has fallen -10.67% in the past 1 week.
The stock has recorded a 20-day Moving Average of 9.51% and the 50-Day Moving Average is 10%. Biocept (NASDAQ:BIOC): On Fridays trading session , Opening price of the stock was $0.63 with an intraday high of $0.63. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.5053. However, the stock managed to close at $0.5787, a loss of 8.14% for the day. On the previous day, the stock had closed at $0.63. The total traded volume of the day was 603,679 shares.
The company Insiders own 6.6% of Biocept shares according to the proxy statements. Institutional Investors own 4.4% of Biocept shares. During last six month period, the net percent change held by insiders has seen a change of 129.39%.
Biocept, Inc. is a cancer diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), tests utilizing a standard blood sample. Its marketed tests are OncoCEE-BR for breast cancer CTC enumeration and analysis, OncoCEE-GA for gastric cancer CTC enumeration and analysis and OncoCEE-LU for non-small cell lung cancer, or NSCLC, CTC enumeration and analysis. Its marketed test and the tests under development for the enumeration and analysis of CTCs utilize its Cell Enrichment and Extraction, or CEE, technology, and the tests under development for the detection and analysis of ctDNA utilize the Companys CEE-Selector technology, each performed on a standard blood sample. The CEE technology is an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing real-time biomarker monitoring with a standard blood sample.